Goldman Sachs upgrades WR Berkley to Buy, raises target to $73
Goldman Sachs upgraded W. R. Berkley Corporation to Buy with a $73 price target, countering a prior downgrade by Wells Fargo to Underweight with a $58 target. HC Wainwright also downgraded ADC Therapeutics SA to Neutral.
*this image is generated using AI for illustrative purposes only.
Goldman Sachs analyst Robert Cox has upgraded W. R. Berkley Corporation from Neutral to Buy and raised the price target to $73 from the previous $71. This positive revision contrasts with recent bearish sentiment from other Wall Street analysts. The new target suggests potential upside from current levels, as WR Berkley shares recently closed at $68.57.
Separately, Wells Fargo analyst Elyse Greenspan had previously downgraded W. R. Berkley Corporation, reducing the stock's rating from Equal-Weight to Underweight and lowering the price target to $58 from $64. Meanwhile, HC Wainwright & Co. analyst Robert Burns downgraded ADC Therapeutics SA from Buy to Neutral, with shares closing at $1.0250.
Analyst Rating Changes
The following table summarizes the recent analyst actions:
| Company | Analyst | Previous Rating | New Rating | Previous Target | New Target |
|---|---|---|---|---|---|
| W. R. Berkley Corporation | Goldman Sachs (Robert Cox) | Neutral | Buy | $71 | $73 |
| W. R. Berkley Corporation | Wells Fargo (Elyse Greenspan) | Equal-Weight | Underweight | $64 | $58 |
| ADC Therapeutics SA | HC Wainwright & Co. (Robert Burns) | Buy | Neutral | N/A | N/A |
The divergent ratings highlight varying valuation expectations and market outlooks for these firms.
What factors might drive W. R. Berkley's stock to reach Goldman Sachs' $73 target despite Wells Fargo's bearish outlook?
How will the market react to the conflicting analyst ratings on W. R. Berkley in the coming weeks?
Could other analysts follow Goldman Sachs' lead and upgrade W. R. Berkley, or will Wells Fargo's downgrade influence sentiment more?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
